Argos Therapeutics to Present at 9th Annual Needham Healthcare Conference
(Durham, N.C.) Argos Therapeutics today announced that Jeffrey Abbey, President and CEO, will present at the 9th Annual Needham Healthcare Conference, being held June 9-10, 2010 at the New York Palace Hotel in New York, NY. Mr. Abbey’s presentation will be delivered on Thursday, June 10, 2010 at 9:40 a.m. Eastern Daylight Time in the Chairman’s Office.
Mr. Abbey will discuss the Company’s Arcelis™ personalized immunotherapy programs in metastatic renal cell carcinoma (RCC) and HIV, both in Phase 2 clinical trials; its anti-IFN-alpha monoclonal antibody, which is in a Phase 1 trial in systemic lupus erythematosus (SLE) patients; and its CD83 recombinant protein, an immunomodulator for inflammatory and autoimmune diseases and transplantation rejection.
Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells - the master switch that turns the immune system on or off. www.argostherapeutics.com

